Key Takeaways
- Phase II is primarily for market learning; Phase III converts learning into operational decisions.
- First-launch companies need longer lead time because capabilities are often built from zero.
- Roadmaps should sequence leadership, access, organization and governance—not only promotional tactics.
- Use illustrative timing; actual sequencing depends on therapy, indication and market.
Emerging biotechnology companies benefit from a shared commercialization roadmap that connects clinical progress to commercial readiness.
This is not a universal calendar. It is a way to organize decisions so capabilities are not discovered eighteen months before launch when they require three years to build. For a visual stage view, see the 36-month launch roadmap.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
